Trial Profile
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Cytarabine; Cytarabine; Fludarabine; Folinic acid; Folinic acid; Hydrocortisone; Methotrexate
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 18 Aug 2020 Results published in the Cancer
- 09 Nov 2018 Status changed from recruiting to discontinued due to slow accrual.
- 22 Aug 2018 Planned End Date changed from 31 Aug 2019 to 31 Aug 2020.